23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
April 14, 2023 16:05 ET
|
23andMe Holding Co.
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral...
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
April 11, 2023 07:00 ET
|
23andMe Holding Co.
Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between...
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023 07:00 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023 16:30 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610...
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023 09:00 ET
|
23andMe Holding Co.
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could help lead to better outcomes for their...
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023 07:00 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people...
23andMe to Present at Upcoming Investor Conferences
February 22, 2023 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023 16:05 ET
|
23andMe Holding Co.
Third quarter revenue grew 18% to $67 million Consumer revenue grew 17% year over year FY2023 financial guidance raised to expected revenue range of $290 to $300 million SOUTH SAN FRANCISCO,...
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022 12:00 ET
|
23andMe Holding Co.
-14 percent of those surveyed say they’re stressed, compared to more than 47 percent in 2020-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down...